Extrait

To evaluate the anti-Hepatitis Bs persistence up to Year 20 after the first vaccine dose of the primary vaccination. To evaluate the prevalence and incidence of other Hepatitis B markers (Hepatitis B surface antigen [HBsAg], antibodies to Hepatitis B core antigen [anti-HBc], HBeAg, antibodies to Hepatitis B envelope antigen [anti-HBe] ) up to Year 20 after the first vaccine dose of the primary vaccination. To evaluate the clinical significance of the HBsAg positive and anti-HBc positive cases observed during the long-term follow-up of this study.

Critère d'inclusion

• Vaccination of healthy newborns of HBsAg+ and/or HBeAg+ mothers against Hepatitis

Liens

• euctr